glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Effects of Once-Weekly on Disease by KDIGO Risk Category in the SUSTAIN 6 A randomized phase 2b trial

The matched control group of individuals without GLP-1 RA prescriptions had a mean (SD) age of 59.3 (13.9) years and included 93 757 females (50.7%) and 91 309 males (49.3%), with 5716 individuals who identified as Asian (3.1%), 33 209 as Black or African American (17.9%), 17 693 as Hispanic (9.6%), 128 769 as not Hispanic or Latino (69.6%), and as 114 315 White (61.8%)

Reduced food intake means less dietary iron

However, meta-analysis encompassing eight CVOTs showed positive impact of GLP-1 receptor agonists on heart failure in patients with type 2 diabetes (T2D)

GIP and GLP-1 bind to their respective receptors: the GIP receptor (GIPR) and GLP-1R to mediate their pleiotropic cellular effects [10]

This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health